首页> 美国卫生研究院文献>Advances in Medicine >Effects of Atorvastatin on Oxidative Stress Biomarkers and Mitochondrial Morphofunctionality in Hyperfibrinogenemia-Induced Atherogenesis
【2h】

Effects of Atorvastatin on Oxidative Stress Biomarkers and Mitochondrial Morphofunctionality in Hyperfibrinogenemia-Induced Atherogenesis

机译:阿托伐他汀对高纤维蛋白原血症诱导的动脉粥样硬化中氧化应激生物标志物和线粒体形态功能的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Relationship between hyperfibrinogenemia (HF), oxidative stress, and atherogenesis was established. Effect of atorvastatin (Ator) was assessed. Wistar male (6 months) rats were studied: Ctr, control, without HF induction; Ctr-Ator, without HF treated with atorvastatin; AI, atherogenesis induced, and AI-Ator, atherogenesis induced and treated with atorvastatin. Atherogenesis was induced by daily adrenaline injection (0.1 mL/day/rat) for 90 days; treatment started 15 days after induction. Fibrinogen (mg/dL) and nitric oxide (NO) were measured in plasma (mM) and superoxide dismutase (SOD) (U/mL) in red cell lysate by spectrophotometry. Slices of aorta were analyzed by electron microscopy (EM). ANOVA and chi-square test were used; P < 0.05 was established. There were no significant differences between Ctr and Ctr-Atorv in fibrinogen, NO, and SOD values. Comparing Ctr with AI an increase of fibrinogen is observed (P < 0.001), but it decreased after administration of atorvastatin in AI-Ator (P < 0.001). NO diminished in AI relative to Ctr and increased in AI-Ator (P < 0.001). SOD showed an increase in AI and AI-Ator compared to Ctr (P < 0.001). EM revealed expansion of intermembrane space and disorganization of crests in AI. In AI-Ator mitochondrial areas and diameters were similar to control. Atorvastatin normalizes HF, stabilizes NO, increases SOD, and produces a partial regression of mitochondrial lesions.
机译:建立高纤维蛋白原血症(HF),氧化应激和动脉粥样硬化之间的关系。评估阿托伐他汀(Ator)的作用。对Wistar雄性(6个月)大鼠进行了研究:Ctr,对照,无HF诱导; Ctr,对照组。 Ctr-Ator,未用阿托伐他汀处理过的HF; AI,诱发动脉粥样硬化,而AI-Ator,诱发动脉粥样硬化并用阿托伐他汀治疗。每天注射肾上腺素(0.1 mL /天/大鼠)诱导90天的动脉粥样硬化。诱导后15天开始治疗。通过分光光度法测定血浆(mM)中的纤维蛋白原(mg / dL)和一氧化氮(NO),以及红细胞裂解液中的超氧化物歧化酶(SOD)(U / mL)。通过电子显微镜(EM)分析主动脉片。采用方差分析和卡方检验。建立P <0.05。 Ctr和Ctr-Atorv之间的纤维蛋白原,NO和SOD值无显着差异。将Ctr与AI进行比较,可以观察到纤维蛋白原的增加(P <0.001),但在AI-Ator中使用阿托伐他汀后血纤维蛋白原的增加(P <0.001)。相对于Ctr,NO的AI减少,而AI-Ator的NO升高(P <0.001)。与Ctr相比,SOD显示AI和AI-Ator增加(P <0.001)。 EM揭示了AI中膜间隙的扩大和波峰的混乱。在AI-Ator中,线粒体的面积和直径与对照相似。阿托伐他汀使HF正常化,稳定NO,增加SOD,并使线粒体病变部分消退。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号